合富中国 (603122)
Cowealth Medical China Co., Ltd.
K-Line Chart
No K-line data available
Company NameHeFu (China) Medical Technology Co., Ltd.
Listing Date2022-02-16
Issue Price4.19RMB
Registered Capital39805.263310k RMB
Legal RepresentativeWang Qiongzhi
Registered AddressRoom 606B, No. 118 Xinling Road, China (Shanghai) Pilot Free Trade Zone
IndustryPharmaceutical Commerce
Main BusinessIntensive business of in vitro diagnostic products, medical product distribution, and other value-added services.
Company ProfileHeFu (China) Medical Technology Co., Ltd. is a channel distributor in the medical circulation field, possessing core competitiveness characterized by long-term mutual benefit and win-win cooperation with domestic and international reagent/consumable and medical equipment original manufacturers, major distributors, and medical institutions.
The company's medical product distribution business primarily focuses on acting as an agent for innovative medical technology equipment from foreign original manufacturers, mainly targeting medical institutions in the Greater China region. The company's core management team mainly originates from the management teams of multinational medical companies in Greater China, possessing an understanding of medical market demands and the ability to assess product market prospects. Over more than a decade, the company has successfully acted as an agent and introduced several advanced foreign medical devices, including those from original manufacturers such as Accuray, TearScience, and Viewray. During the cooperation periods, it has received awards from the original manufacturers, such as Best Global Distributor and Best Performance. The related agency products cover over 70 hospitals, and the company provides long-term maintenance services. The company's medical product distribution business also includes providing circulation services within the medical product channel network, actively leveraging channel advantages with the goal of embedding into the channel networks dominated by upstream original manufacturers and their major distributors.
Stock Details
1. Key Indicators
- Total Shares(W): 39805.26
- Circulating A-Shares(W): 39805.26
- Earnings Per Share(RMB): -0.03
- Net Assets Per Share(RMB): 2.78
- Operating Revenue(W RMB): 54886.23
- Total Profit(W RMB): -1459.45
- **Net Profit Attributable to Parent(W RMB) **: -1238.62
- Net Profit Growth Rate(%): -146.65
- Weighted Return on Equity(%): -1.06
- Operating Cash Flow Per Share(RMB): 0.26
- Undistributed Profit Per Share(RMB): 0.16
- Capital Reserve Per Share(RMB): 1.50
2. Main Business
The main business covers:
- Distributor in the medical circulation field
3. Company Basic Information
- Company Name: Cowealth (China) Medical Technology Co., Ltd.
- Listing Date: 2022-02-16
- Industry: Wholesale Trade
- Address: Guangqi Building, No. 456 Hongcao Road, Xuhui District, Shanghai
- Website: https://www.cowealth.com
- Company Profile: The company was established by the overall transformation of Cowealth Limited into a joint stock company. On March 18, 2019, the board of Cowealth Limited resolved to approve the overall transformation into a foreign-invested joint stock company as of the base date of January 31, 2019. The audited net assets of Cowealth Limited as of January 31, 2019, totaling RMB 336,001,547.75, were converted into 212,015,683 shares at a ratio of 1:0.6310. The remaining RMB 123,985,864.75 was recorded into the company's capital reserve. After the股份制改造, the name was changed to Cowealth (China) Medical Technology Co., Ltd. On the same day, Cowealth Hong Kong, Quezi Limited, Yuancheng Partnership, Yuanang Partnership, Yuanyi Partnership, Yuanyu Partnership, and Huajin Limited signed the "Sponsor Agreement for the Overall Transformation of Cowealth (China) Medical Technology Trade Co., Ltd. into a Foreign-invested Joint Stock Company." On March 22, 2019, all sponsors held the founding meeting and the first interim shareholders' meeting of 2019, reviewing and approving the relevant proposals for the overall transformation. On March 29, 2019, the China (Shanghai) Pilot Free Trade Zone Management Committee issued the "Foreign-invested Enterprise Change Filing Receipt" (No. BSQ201901050). On April 19, 2019, the Shanghai Municipal Administration for Market Regulation reissued the "Business License" (Unified Social Credit Code: 91310000703011187G). On April 22, 2019, according to the "Capital Verification Report" (Shang Hui Shi Bao Zi [2019] No. 3878) issued by Shanghui Certified Public Accountants, as of April 19, 2019, the issuer had converted the audited net assets of Cowealth Limited as of January 31, 2019 into a total of 212,015,683 shares, with a total share capital of RMB 212,015,683.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Cowealth (Hong Kong) Holding Co., Ltd. | General Legal Person | 21893.79 | 55.00 |
| 2 | Quezi Limited | General Legal Person | 212.67 | 0.53 |
| 3 | Lianfang Limited | General Legal Person | 122.84 | 0.31 |
| 4 | Shanghai Yuanyu Enterprise Management Consulting Center (Limited Partnership) | General Legal Person | 84.71 | 0.21 |
| 5 | Ping An Life Insurance Company of China, Ltd. - New Dividend Policy No. 8 - Mandate (Bank of Communications) | Insurance | 76.31 | 0.19 |
5. Concept Sectors
- Smart Healthcare
- Artificial Intelligence
- AI in Healthcare
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information